drugset
drugset / Trial / NCT02359357

FTIH - Single and Repeat Oral Doses of FDL169 in Healthy Volunteers

NCT02359357 ↗

Phase 1 Completed 130 enrolled Flatley Discovery Lab LLC
RandomizedParallel-groupTriple-blind

Summary

To determine the safety and tolerability of single and multiple escalating doses of FDL169 in healthy male subjects.

Timeline

Start
2015-01
Primary completion
2016-03
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Subject FDL169 Small molecule — Oral

Indications

cystic fibrosis